Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb] SCHEMBL159244 | 1.00 | MAPT (1.00) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL4217741 | 0.96 | MAPT (0.93) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL3029764 | 0.92 | MAPT (1.00) | MAPTCDK2KMT2AMEN1NPC1 | |
| 5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb] SCHEMBL7821604 | 0.90 | MAPT (0.82) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL6374917 | 0.90 | MAPT (0.82) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL14280729 | 0.87 | CDK2 (0.77) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL4212246 | 0.84 | MAPT (1.00) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL3843127 | 0.82 | KMT2A (0.71) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL27577353 | 0.82 | MAPT (0.69) | MAPTCDK2KMT2AMEN1NPC1 | |
| SCHEMBL4198828 | 0.81 | MAPT (0.80) | MAPTCDK2KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023021175-A1 | COMPOSITION FOR USE IN THE TREATMENT OF GLIOMA | SISSA - SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI (IT) | 2023-02-23 | — | — | WO | claimed |
| CN-115518163-A | Methods of medical treatment using SUR1-TRPM4 channel inhibitors | 生物切萨皮克有限责任公司 | 2022-12-27 | — | — | CN | claimed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| CN-112105378-B | Glucose oxidase composition as anticonvulsant for neonates | 宾夕法尼亚州研究基金会 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025014777-A1 | INHIBITION OF CLIC1 TO TREAT OBESITY AND HEART FAILURE | CLICBIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | disclosed |
| CN-117715678-A | Electrode assembly for applying a Tumor Treatment Field (TTFIELD) using an anisotropic sheet of material | 诺沃库勒有限责任公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| EP-4255431-A1 | SOLID FORMS OF EMETINE | Acer Therapeutics Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116626123-A | Single cell intracellular nano PH probe | 加利福尼亚大学董事会 | 2023-08-22 | — | — | CN | disclosed |
| CN-115835878-A | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | 钙医学公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115518163-A | Methods of medical treatment using SUR1-TRPM4 channel inhibitors | 生物切萨皮克有限责任公司 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | disclosed |
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | IFM MANAGEMENT, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120209-A1 | SOLID FORMS OF EMETINE | ACER THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3989722-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | Zymo Research Corporation (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | NLRP3, NLRP1, TNF | MAPT 895/4885CDK2 4786/4885KMT2A 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.